Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Povorcitinib Drug Interaction with Oral Contraceptives in Healthy Females
NCT06380205Phase 1Completed
- Sponsor
- Incyte
- Start
- May 2024
- Primary completion
- Jun 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of povorcitinib in hidradenitis suppurativa (HS), prurigo nodularis (PN) and Vitiligo, sponsored by Incyte. Primary endpoints: Levonorgestrel (LNG) concentration in plasma and Ethinyl estradiol (EE) concentration in plasma. Started May 2024; status: completed.
02
Drugs
povorcitinib
03
Conditions
hidradenitis suppurativa (HS)prurigo nodularis (PN)Vitiligo
Beyond the preview
Go deeper on NCT06380205.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06380205.